Published in Naunyn Schmiedebergs Arch Pharmacol on March 01, 1980
The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man. Br J Clin Pharmacol (1985) 0.91
The effects of yohimbine on presynaptic and postsynaptic events during sympathetic nerve activation in cattle iris: a critique of presynaptic receptor theory. Br J Pharmacol (1983) 0.87
Differential blockade of alpha-adrenoceptors by indoramin. Br J Clin Pharmacol (1984) 0.86
The role of presynaptic alpha-adrenoceptors in the regulation of blood pressure in the conscious rabbit. Br J Pharmacol (1982) 0.81
Macro- and microvascular effects of nitrous oxide in the rat. Anesth Prog (1992) 0.75
An assessment of health hazard/health risk appraisal. Am J Public Health (1982) 3.12
Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med (1991) 2.85
A functional basis for classification of alpha-adrenergic receptors. Life Sci (1977) 2.69
The history of commonly used dental elevators. Br Dent J (2008) 2.57
Prazosin: the first-dose phenomenon. Br Med J (1976) 2.51
Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science (1994) 2.50
Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway. Nature (1999) 2.24
Autonomic ganglionitis with severe hypertension, migraine, and episodic but fatal hypotension. Neurology (1996) 2.03
Left handed GDP's and students. Br Dent J (1995) 2.01
Solution-phase library screening for the identification of rare clones: isolation of an alpha 1D-adrenergic receptor cDNA. Mol Pharmacol (1991) 1.87
Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem (2001) 1.86
Structure and function in rhodopsin. Studies of the interaction between the rhodopsin cytoplasmic domain and transducin. J Biol Chem (1992) 1.82
Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol (1989) 1.67
Experience with prazosin in the treatment of patients with severe hypertension. Med J Aust (1976) 1.62
Drug therapy. Prazosin. N Engl J Med (1979) 1.62
Exaggerated physiologic speckled mottling of the limbs. Arch Dermatol (1985) 1.53
Cancer of endometrium and prolonged estrogen therapy. J Am Med Assoc (1946) 1.50
The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. J Biol Chem (1994) 1.49
Inhibition of monoamine oxidase in man by furazolidone. Clin Pharmacol Ther (1968) 1.40
More supernumeraries? Br Dent J (1997) 1.39
Minoxidil--an alternative to nephrectomy for refractory hypertension. N Engl J Med (1973) 1.38
The structure of rat preproatrial natriuretic factor as defined by a complementary DNA clone. Science (1984) 1.32
Alpha blocking action of the antihypertensive agent, prazosin. J Pharmacol Exp Ther (1977) 1.28
Targeted alpha(1A)-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res (2001) 1.28
Adrenergic component of renin release induced by vasodilating antihypertensive drugs in the rat. Circ Res (1973) 1.27
The effect of mental arithmetic in normotensive and hypertensive subjects, and its modification by beta-adrenergic receptor blockade. Br J Clin Pharmacol (1977) 1.27
"Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int (1995) 1.22
Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci U S A (1998) 1.22
Non-alpha-helical elements modulate polytopic membrane protein architecture. J Mol Biol (2001) 1.21
Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol (1996) 1.21
Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem (1995) 1.20
Hyperinnervation of the airways in transgenic mice overexpressing nerve growth factor. Am J Respir Cell Mol Biol (1998) 1.20
Cardiovascular responses to exercise as functions of absolute and relative work load. J Appl Physiol Respir Environ Exerc Physiol (1983) 1.20
The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP. Biochemistry (1997) 1.18
Renal alpha-1 and alpha-2 adrenergic receptors: biochemical and pharmacological correlations. J Pharmacol Exp Ther (1981) 1.15
Genomic organization and expression of the human alpha 1B-adrenergic receptor. J Biol Chem (1992) 1.14
Drug therapy: clonidine, a new antihypertensive drug. N Engl J Med (1975) 1.14
Cloning of the gene and cDNA for human heart chymase. J Biol Chem (1991) 1.13
Influence of dosage and dietary sodium on the first-dose effects of prazosin. Br Med J (1977) 1.10
Evidence for the release of bradykinin in carcinoid syndrome. J Clin Invest (1966) 1.10
Biosynthesis and secretion of proatrial natriuretic factor by cultured rat cardiocytes. Science (1985) 1.10
Abnormal cardiovascular regulation in the mitral valve prolapse syndrome. Am J Cardiol (1983) 1.10
Phorbol esters inhibit alpha 1-adrenergic effects and decrease the affinity of liver cell alpha 1-adrenergic receptors for (-)-epinephrine. J Biol Chem (1986) 1.09
Supersensitivity to tyramine during monoamine oxidase inhibition in man. Mechanism at the level of the adrenergic neuron. Clin Pharmacol Ther (1968) 1.09
Release of the neuregulin functional polypeptide requires its cytoplasmic tail. J Biol Chem (1998) 1.07
Juvenile plantar dermatosis. Clin Exp Dermatol (1987) 1.07
GTP binding and signaling by Gh/transglutaminase II involves distinct residues in a unique GTP-binding pocket. J Biol Chem (2000) 1.06
Cloning, expression, and tissue distribution of the rat homolog of the bovine alpha 1C-adrenergic receptor provide evidence for its classification as the alpha 1A subtype. Mol Pharmacol (1994) 1.05
Characterization of an imidazoline/guanidinium receptive site distinct from the alpha 2-adrenergic receptor. J Biol Chem (1989) 1.04
Role of muscle mass and mode of contraction in circulatory responses to exercise. J Appl Physiol (1985) (1985) 1.04
Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. N Engl J Med (1975) 1.02
Intracellular mediators of c-fos induction. Cold Spring Harb Symp Quant Biol (1988) 1.01
Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther (2005) 1.01
Indoramin and prazosin as adjuncts to beta adrenoceptor blockade in hypertension. Clin Pharmacol Ther (1979) 1.00
Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific. Mol Pharmacol (1993) 1.00
Spurious systolic hypertension in youth. Vasc Med (2000) 1.00
Role of renal prostaglandins in sympathetically mediated renin relase in the rat. J Clin Invest (1979) 1.00
Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet (1982) 1.00
Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. Ann Intern Med (1980) 0.99
Alpha1-adrenergic receptor signaling via Gh is subtype specific and independent of its transglutaminase activity. J Biol Chem (1996) 0.99
Autosomal dominant junctional epidermolysis bullosa. Br J Dermatol (2009) 0.99
A novel guanine nucleotide-binding protein coupled to the alpha 1-adrenergic receptor. II. Purification, characterization, and reconstitution. J Biol Chem (1990) 0.99
Minoxidil and the treatment of severe hypertension. N Engl J Med (1980) 0.98
Pathogenesis of inherited forms of dilated cardiomyopathy. N Engl J Med (1999) 0.98
Insulin-like growth factor (IGF-I) induces myotube hypertrophy associated with an increase in anaerobic glycolysis in a clonal skeletal-muscle cell model. Biochem J (1999) 0.97
Sodium chloride suppression of renin release in the unanesthetized rat. Endocrinology (1975) 0.97
A novel putative protein-tyrosine phosphatase contains a BRO1-like domain and suppresses Ha-ras-mediated transformation. J Biol Chem (1998) 0.97
Renin suppression by DOC and NaCl in the rat. Am J Physiol (1971) 0.97
Placental transmission of cephaloridine. J Obstet Gynaecol Br Commonw (1967) 0.96
Endotoxin-induced kinin (bradykinin) formation: activation of Hageman factor and plasma kallikrein in human plasma. Life Sci (1970) 0.95
Epithelial markers in primary skin cancer: an immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. Histopathology (1984) 0.95
Outcomes of trauma patients who survive prolonged lengths of stay in the intensive care unit. J Trauma (2000) 0.95
Percutaneous iontophoresis of prednisolone--a pharmacokinetic study. Clin Exp Dermatol (1986) 0.95
Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study. Am J Cardiol (1983) 0.95
Increased pulmonary vascular resistance with systemic hypertension. Effect of minoxidil and other antihypertensive agents. Am J Cardiol (1977) 0.94
Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. Clin Pharmacol Ther (1975) 0.94
Renal alpha 2-adrenoceptors and the adenylate cyclase-cAMP system: biochemical and physiological interactions. Am J Physiol (1987) 0.94
Evidence for a renal alpha-adrenergic receptor inhibiting renin release. Circ Res (1976) 0.94
A novel guanine nucleotide-binding protein coupled to the alpha 1-adrenergic receptor. I. Identification by photolabeling or membrane and ternary complex preparation. J Biol Chem (1990) 0.94
Renal nerve stimulation causes alpha 1-adrenoceptor-mediated sodium retention but not alpha 2-adrenoceptor antagonism of vasopressin. Circ Res (1985) 0.93
Angiotensin II- and angiotensin 3-induced aldosterone release vivo in the rat. Science (1974) 0.93
Molecular characterization of adrenergic receptors. Circ Res (1985) 0.93
Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3. Am J Physiol Gastrointest Liver Physiol (2006) 0.93
Serum-mediated enhancement of ANF accumulation in the culture medium of cardiac atriocytes. Biochem Biophys Res Commun (1986) 0.93
Renin release, an artifact of anesthesia and its implications in rats. Proc Soc Exp Biol Med (1975) 0.92
Evolutionary conservation of both the hydrophilic and hydrophobic nature of transmembrane residues. J Theor Biol (1995) 0.92
Mast cells and cancer of the cervix. Surg Gynecol Obstet (1966) 0.91
Letter: Hypotension during angiotensin blockade with saralasin. Lancet (1975) 0.91
Alpha2-adrenoceptors and cellular cAMP levels in single nephron segments from the rat. Am J Physiol (1985) 0.90
Glycosylation of the mammalian alpha 1-adrenergic receptor by complex type N-linked oligosaccharides. Mol Pharmacol (1987) 0.89
Organ specificity of angiotensin II and Des-aspartyl angiotensin II in the conscious rat. J Pharmacol Exp Ther (1976) 0.89
Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest (1995) 0.89
NADP improves the efficiency of cholera toxin catalyzed ADP-ribosylation in liver and heart membranes. Biochem Biophys Res Commun (1986) 0.89
Malignant hypertension secondary to renal artery stenosis in children. Ann Surg (1966) 0.89
Enhanced release of endothelium-derived relaxing factor in mineralocorticoid hypertension. Hypertension (1992) 0.89